New Cloud Medical
新云医疗
New Cloud Medical (新云医疗) is a Beijing-based chronic pain medtech company founded in 2016 by CEO Zhao Yun, who previously spent eight years working in hospitals . The company develops neuromodulation devices and minimally invasive instruments for chronic pain management, including China's first AI closed-loop implantable rechargeable spinal cord stimulation system (NewStim®) and the NewMild® percutaneous lumbar decompression kit for lumbar spinal stenosis .
Its core technical approach combines AI, spinal cord interfaces, and a "industry-university-research-medical-application" collaboration model with institutions including the Chinese Academy of Sciences and China Rehabilitation Research Center . In September 2025, the company closed a tens-of-millions RMB Series B+ round led by Dalton Venture, bringing its total fundraising to six rounds; the capital is directed toward clinical trials, regulatory approvals, and US market entry . Dalton Venture has framed its investment as a long-term bet on New Cloud Medical's potential to become a global player in pain management devices .
AI-generated — may contain errors, please verify.
Coverage
From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies
"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Vol.1 Finding a Switch for That Chronic Pain You've Endured for So Long | Column · The New Era's Unicorns
In 2025, the global chronic pain treatment market will grow to 500 billion yuan.
Xinyun Medical Closes Tens of Millions of RMB in Series B+ Funding Led by Dalton Venture, Building Innovative Devices and Neuromodulation Solutions for Chronic Pain | Dalton News
AI is emerging as a new engine for breaking through in pain treatment
